DFTT - ETF AI Analysis
Top Page
DF Tactical 30 ETF (DFTT)
DFTT vs. SPDR S&P 500 ETF (SPY)
- AUM
- 32.97M
- Region
- North America
- Expense Ratio
- 0.70%
- Beta
- 1.36
- Issuer
- Donoghue Forlines
- Inception Date
- Nov 11, 2025
- Dividend Yield
- 0.14%
- Asset Class
- Equity
- Index Tracked
- DF Risk-Managed Tactical Top 30 Index - Benchmark TR Gross
DFTT Summary
DF Tactical 30 ETF (DFTT) is a U.S. stock fund that follows the DF Risk-Managed Tactical Top 30 Index, holding 30 large American companies with strong recent performance. It focuses mainly on technology and health care, with well-known names like Micron, AMD, Eli Lilly, JPMorgan Chase, Intel, and Johnson & Johnson. Investors might consider this ETF for growth potential and simple diversification across leading large-cap stocks, without having to pick individual winners. However, because it leans heavily toward fast-moving tech and health care companies, its price can be volatile and may go up and down sharply with market swings.
How much will it cost me?
The DF Tactical 30 ETF (DFTT) has an expense ratio of 0.7%, meaning you’ll pay $7 per year for every $1,000 invested. This is higher than the average for ETFs because it is actively managed, using a sophisticated strategy to select and monitor the top 30 U.S. large-cap stocks with strong momentum.
What would affect this ETF?
The DF Tactical 30 ETF (DFTT) could benefit from continued growth in the technology sector, which makes up over half of its portfolio, especially if innovation and demand for tech products remain strong. However, the ETF may face challenges if interest rates rise, as higher borrowing costs can negatively impact large-cap companies, particularly in sectors like technology and consumer cyclical. Additionally, economic slowdowns or regulatory changes targeting major U.S. corporations could create headwinds for its top holdings.
DFTT Top 10 Holdings
DF Tactical 30 is leaning hard into U.S. tech momentum, with chip makers AMD and Micron doing much of the heavy lifting as their shares keep rising on AI and data-center optimism. Cybersecurity names like CrowdStrike and Palo Alto Networks add more tech fuel, though their rich valuations could cool the pace. On the health care side, Eli Lilly and AbbVie are steady contributors, while Johnson & Johnson has been more mixed, occasionally losing steam. JPMorgan is one of the few financial anchors, but its recent softness slightly drags this otherwise tech-heavy, U.S.-focused story.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 LLY | Eli Lilly & Co | 6.13% | $1.94M | $1.33T | 67.86% | 72Outperform |
 AMD | Advanced Micro Devices | 4.23% | $1.34M | $824.07B | 98.09% | 73Outperform |
 MU | Micron | 4.31% | $1.37M | $1.00T | 294.96% | 79Outperform |
 JPM | JPMorgan Chase | 4.39% | $1.39M | $895.92B | 8.92% | 72Outperform |
 ABBV | AbbVie | 4.23% | $1.34M | $521.11B | 29.22% | 66Neutral |
 JNJ | Johnson & Johnson | 4.11% | $1.30M | $657.68B | 44.51% | 78Outperform |
 CRWD | CrowdStrike Holdings | 3.76% | $1.19M | $256.42B | 85.96% | 67Neutral |
 TXN | Texas Instruments | 3.64% | $1.16M | $274.90B | 87.43% | 78Outperform |
 PANW | Palo Alto Networks | 3.54% | $1.12M | $299.56B | 67.62% | 73Outperform |
 TMO | Thermo Fisher | 3.61% | $1.15M | $257.71B | 25.31% | 72Outperform |
DFTT Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For DFTT, the sentiment is Negative. The current price of 29.10 is below the 20-day moving average (MA) of 30.01, below the 50-day MA of 30.18, and above the 200-day MA of 28.59, indicating a neutral trend. The MACD of -0.27 indicates Positive momentum. The RSI at 40.99 is Neutral, neither overbought nor oversold. The STOCH value of 72.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DFTT.
DFTT Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| DFTT | $29.10 | $34.00(16.83% Upside) | $32.97M | 0.70% | 74Outperform |
 PRMR | $28.30 | $34.26(21.03% Upside) | $93.63M | 1.00% | 73Outperform |
 SPXE | $80.85 | $100.26(24.00% Upside) | $86.64M | 0.09% | 74Outperform |
 FCUS | $36.61 | $47.35(29.34% Upside) | $86.02M | 0.80% | 67Neutral |
 NULC | $54.91 | $68.30(24.38% Upside) | $81.33M | 0.21% | 74Outperform |
 QARP | $68.79 | $79.92(16.18% Upside) | $79.50M | 0.19% | 73Outperform |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DFTT | DF Tactical 30 ETF | 29.10 | 4.03 | 16.06% | |
| PRMR | PeakShares RMR Prime Equity ETF | 28.30 | 3.32 | 13.31% | |
| SPXE | ProShares S&P 500 Ex-Energy ETF | 80.85 | 7.60 | 10.37% | |
| FCUS | Pinnacle Focused Opportunities ETF | 36.61 | 2.64 | 7.78% | |
| NULC | Nuveen ESG Large-Cap ETF | 54.91 | 7.00 | 14.61% | |
| QARP | Xtrackers Russell 1000 US Quality at a Reasonable Price ETF | 68.79 | 11.60 | 20.27% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.